This is the authors' abstract. We don't add key points for this paper.
Recent advances in acute myeloid leukemia (AML) come from studies investigating older adults aged <60 years, those aged ≥75 years, or less fit adults. Uncertainty exists for the management of otherwise healthy adults with AML in their 60s and 70s, which also represents a significant proportion of AML cases. We discuss current considerations in older, fit adults with AML, including determination of fitness, factors beyond fitness that should be assessed, and challenges and innovations to improve patient outcomes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Abedin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: